Core Viewpoint - Corcept Therapeutics Incorporated is facing a class action lawsuit for alleged violations of securities laws, specifically for making false and misleading statements regarding its product candidate, relacorilant, during the class period from October 31, 2024, to December 30, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Corcept misled investors by stating that relacorilant was "approaching approval" despite receiving warnings from the FDA about insufficient clinical data [1]. - The deadline for shareholders to participate in the lawsuit is April 21, 2026 [1]. - The class action is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. Group 2: Company Background - Corcept Therapeutics is publicly traded on NASDAQ under the ticker symbol CORT [1]. - The company is accused of making materially misleading public statements throughout the class period, which could have significant implications for its stock value and investor trust [1].

Core Viewpoint - Corcept Therapeutics is facing a class action lawsuit due to alleged misrepresentations regarding the approval process of its drug relacorilant, which has led to significant stock price declines following negative FDA feedback [4][5][6]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Corcept securities between October 31, 2024, and December 31, 2025, with a deadline for filing a lead plaintiff motion set for April 21, 2026 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Company Overview - Corcept Therapeutics specializes in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a key product candidate for treating hypercortisolism [3]. Group 3: Allegations Against Corcept - The lawsuit claims that Corcept misled investors by stating that the relacorilant New Drug Application (NDA) was well-supported and nearing approval, despite known concerns from the FDA regarding clinical evidence [4]. - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating that additional evidence was needed for a favorable benefit-risk assessment, resulting in a stock price drop of over 50% [5]. - A redacted copy of the CRL published by the FDA on January 30, 2026, highlighted concerns about the adequacy of clinical studies submitted, and prior warnings from the FDA about potential review issues were noted [6].

"Company†) (NASDAQ: NAVN) common stock pursuant and/or traceable to the Registration Statement issued in connection with the Company's October 31, 2025 initial public offering (the "IPO†or the "Offering†). Navan investors ha...## Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Lakeland Industries, Inc. (LAKE) Shareholders To Inquire About Securities Fraud Class ActionLOS ANGELES--([BUSINESS WIRE])--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder right ...

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, s ...

Core Viewpoint - A securities fraud class action lawsuit has been initiated against Corcept Therapeutics Incorporated, with a deadline for potential lead plaintiffs to file papers by April 21, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [4]. - The allegations include misrepresentations made by the defendants regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5]. Group 2: Investor Actions - Investors who wish to participate in the class action can contact the Investor Relations Manager for more information and to discuss their legal rights and options [2][8]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3].

Core Viewpoint - ClaimsFiler is reminding investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics, related to undisclosed material information during the Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Corcept and its executives failed to disclose material information, violating federal securities laws during the Class Period from October 31, 2024, to December 30, 2025 [3]. - The complaint specifically mentions that Corcept misled investors regarding the likelihood of FDA approval for its product candidate, relacorilant, following its New Drug Application submission [4]. - Following the disclosure of a Complete Response Letter from the FDA on December 31, 2025, which indicated that additional evidence of effectiveness was needed, Corcept's share price fell by $35.40, or 50.4%, from $70.20 to $34.80 [4]. Group 2: Legal and Investor Support - The case is officially titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 [5]. - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period†). Corcept investors have until April 21, 2026 to file a lead plaintiff motion. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materiall ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Corcept Therapeutics Incorporated common stock during the specified Class Period, indicating potential legal recourse for affected investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Corcept common stock between October 31, 2024, and December 30, 2025, inclusive [1]. - Investors who purchased shares during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the status of its New Drug Application (NDA) for relacorilant, claiming strong support from clinical trials while the FDA had raised concerns about the evidence [5]. - Defendants reportedly assured investors that there were no impediments to NDA approval, despite known risks that it might not be approved [5].

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, both dates inclusive (the “Class Period”), have until April 21, 2026 to seek appointment as lead plaintiff of the Corcept class action lawsuit. Captioned Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), the Corcept cla ...

Key Takeaways CORT posted Q4 EPS of 20 cents, missing estimates. Revenues rose 11% Y/Y to $202.1M in Q4 2025.CORT expects 2026 revenues of $900M-$1B. FDA decision on relacorilant in ovarian cancer is due in July 2026.Corcept received the FDA's CRL for relacorilant in Cushing's syndrome and is engaging in the next steps.Corcept Therapeutics (CORT) reported fourth-quarter 2025 earnings of 20 cents per share, which missed the Zacks Consensus Estimate of 27 cents. The company had reported earnings of 26 cents p ...